The European Association for the Study of Diabetes (EASD) invited Prof Roy Taylor to give the 56th Claude Bernard lecture at EASD 2024 in Madrid last September.
EASD have published an interesting interview with Vivienne Parry, which puts Roy Taylor's work into context, and the superb lecture itself.
In the lecture Roy Taylor covers his early work on glycogen, the pivotal Counterpoint and Counterbalance studies, the DiRECT study which led to the NHS Pathway to Remission, and the recent ReTUNE study of remission of Type 2 for those of normal weight.
IMHO the 56th Claude Bernard lecture is an opportunity for Diabetes UK to re-emphasise the importance of its support for the Counterpoint study almost 20 years ago. It proved a diagnosis of Type 2 Diabetes need no longer be a life sentence for many people.
EASD have published an interesting interview with Vivienne Parry, which puts Roy Taylor's work into context, and the superb lecture itself.
In the lecture Roy Taylor covers his early work on glycogen, the pivotal Counterpoint and Counterbalance studies, the DiRECT study which led to the NHS Pathway to Remission, and the recent ReTUNE study of remission of Type 2 for those of normal weight.
IMHO the 56th Claude Bernard lecture is an opportunity for Diabetes UK to re-emphasise the importance of its support for the Counterpoint study almost 20 years ago. It proved a diagnosis of Type 2 Diabetes need no longer be a life sentence for many people.
